CSI Market
Sign In | Register

Teva Pharmaceutical Industries Limited (TEVA) Annual Cash Flow Statement

Annual · GAAP · USD millions
Access TEVA quarterly Cash Flow →
Quarterly cash flow trends provide additional context on Teva Pharmaceutical Industries Limited's liquidity and ability to support ongoing operations and capital needs.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Annual Report, GAAP in USD millions
ITEM 		(Dec 31 2025)
12 Months 		(Dec 31 2024) (Dec 31 2023) (Dec 31 2022) (Dec 31 2021)
Operating Activities
Income1,410.00
Depreciation & amortization421.00
Amortization of Other Assets581.00
Extraordinary Item, Gain (Loss), Insurance Assets, Accretion Expense0.00
Goodwill, Impairment Loss54.00
Provision For Loan Losses Expensed0.00
Increase (Decrease) in Inventories152.00
Research and Development in Process0.00
Gain (Loss) on Disposition of Assets-22.00
Share-based Compensation157.00
Income (Loss) from Equity Method Investments15.00
Financial Instruments and Foreign Currency Transaction0.00
Deferred Income Taxes Net And Uncertain Tax Positions-671.00
Gain From Revaluation Of Investments-
Venezuela Remeasurement Impact-
Research And Development Expense-
Increase Decrease In Certain Current Liabilities Excluding Debt-15.00
Impairment Of Investments-
Profit From Sale Of Long Lived Assets And Investment1,028.00
Income taxes81.00
Losses/ -gains on Investments net0.00
Accounts Receivable0.00
Accounts Payable0.00
Accrued Expense0.00
Deferred Revenue and Customer Advances and Deposits0.00
Prepaid Expense and Other Assets0.00
Other Working Capital1,366.00
Other Noncash Income (Expense)0.00
Other net7.00
Payments for (Proceeds from) Other Operating Activities-137.00
Discontinued operations0.00
Net Cash flow from Operating Activities1,649.00
Investing Activities
Capital Expenditures501.00
Sale of Capital Items0.00
Proceeds from Sale and Maturity of Marketable Securities0.00
Short-term Investments Acq.0.00
Real Estate Investments0.00
Payment To Aquire Marketable Securities And Other Assets-
Cash Flows Between Transferor And Transferee Beneficial Interest-
Payment To Acquire Marketable Securities And Other Assets-57.00
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Proceeds from Sale, Maturity and Collection of Investments42.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Payments to Acquire Businesses, Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Proceeds from Divestiture of Businesses34.00
Accounts payable0.00
Receivables4,513.00
Payments for (Proceeds from) Other Investing Activities-5.00
Other Net1,214.00
Discontinued operations0.00
Net Cash Flow from Investing Activities737.00
Financing Activities
Short-term debt Net0.00
Other borrowing transactions4,505.00
Long-term debt - borrowings2,298.00
Long-term debt - repayments4,112.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock47.00
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net41.00
Other net-3,259.00
Proceeds From Senior Notes Net Of Issuance Costs-
Proceeds From Long Term Loans And Other Long Term Liabilities-
Proceeds From Senior Notes Net-
Payments Of Dividends Preferred Stock-
Payments Related To Tax Withholding For Shares And Dividend-
Repayment Of Convertible Debt-
Debt Conversion Converted Instrument Amount-
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents3,300.00
Proceed From Minority Non Controlling Shareholders-38.00
Dividends Paid To Non Controlling Interests-340.00
Payments of Ordinary Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities-2,151.00
Effect of exchange rate on cash flow21.00
Discontinued operations0.00
Free Cash Flow2,150.00
Total Cash Flow256.00
4 historic quarters locked

Sign in to unlock the full Teva Pharmaceutical Industries Limited cash flow history.

Sign In Create Free Account

About Teva Pharmaceutical Industries Ltd Annual Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-K filings and normalized by CSIMarket.

Source & verification

  • Form: 10-K (Period: 20251231)
  • Filed with the SEC: February 3, 2026
  • Source: d93612d10k.htm

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001193125-26-034532

Figures are derived from filed reports and may be restated. Historical data is subject to revision.

Untitled Document 





                    


    



  Get the full CSIMarket dataset:
  Subscribe
  API
  License